R9Q Panoramica delle azioni Recce Pharmaceuticals Ltd, scopre, sviluppa e commercializza antinfettivi sintetici in Australia, Regno Unito e Stati Uniti. Maggiori dettagli
Analisi del rischio + 2 più rischi
Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Recce Pharmaceuticals Ltd Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Recce Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione AU$0.26 Massimo di 52 settimane AU$0.38 Minimo di 52 settimane AU$0.23 Beta 1.1 Variazione di 1 mese 2.33% Variazione a 3 mesi -10.20% Variazione di 1 anno -14.84% Variazione a 3 anni -58.75% Variazione a 5 anni n/a Variazione dall'IPO -18.49%
Notizie e aggiornamenti recenti
Recce Pharmaceuticals Ltd Receives Approval from Indonesia's Drug and Food Authority for Registrational Phase 3 Trial of Recce®? 327 Topical Gel in Diabetic Foot Infections Dec 11
Recce Pharmaceuticals Ltd Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of Recce®?327 Topical Gel in Diabetic Foot Infections Nov 12
Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Nov 06
Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Oct 10
Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024 Sep 16
New major risk - Revenue and earnings growth Jul 16 Vedi altri aggiornamenti
Recce Pharmaceuticals Ltd Receives Approval from Indonesia's Drug and Food Authority for Registrational Phase 3 Trial of Recce®? 327 Topical Gel in Diabetic Foot Infections Dec 11
Recce Pharmaceuticals Ltd Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of Recce®?327 Topical Gel in Diabetic Foot Infections Nov 12
Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Nov 06
Recce Pharmaceuticals Announces Recruitment Passes Halfway in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections Oct 10
Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 06, 2024 Sep 16
New major risk - Revenue and earnings growth Jul 16
Recce Pharmaceuticals Announces Positive Preclinical Efficacy Data Against WHO Priority Pathogen Acinetobacter Baumannii Jul 10 Recce Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 2 million.
Recce Pharmaceuticals Reports Positive Data from Phase I/Ii Urinary Tract Infection (Uti) / Urosepsis Rapid Infusion Trial of Recce® 327 Jul 03
Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections Jun 25
Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization’S List of Antibacterial Products in Clinical Development Jun 20
Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial May 18
Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study May 15
Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration May 09
New major risk - Revenue and earnings growth May 08
Recce Pharmaceuticals Ltd. Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis Apr 30
Recce Pharmaceuticals Ltd. Completes 5,000 RECCE 327 Doses Week Under Good Manufacturing Practice Apr 17
Recce Pharmaceuticals Ltd Receives New Patent in Israel for Recce Anti-Infectives Apr 05
New major risk - Revenue and earnings growth Mar 27
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of Recce® 327 for Urinary Tract Infections and Urosepsis Mar 20
Recce Pharmaceuticals Ltd Doses Next Cohort in Phase I/II Trial of RECCE 327 for Urinary Tract Infections and Urosepsis Mar 14
New major risk - Share price stability Mar 13
Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE 327 for the Treatment of Diabetic Foot Infections Jan 23
Recce Pharmaceuticals Receives Ausindustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program Dec 20
Recce Pharmaceuticals Ltd Reports Positive Preclinical Data of RECCE 327 Against Gonorrhoeae Dec 19
Recce Pharmaceuticals Limited Announces Canadian Patent Granted for Recce® Anti-Infectives Nov 23
Recce Pharmaceuticals Ltd Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis Nov 10
Recce Pharmaceuticals Ltd Announces Safety Committee Approves Faster Infusion Rate in Phase I/Ii Trial of Recce® 327 for Urinary Tract Infections and Urosepsis Oct 26 Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million. Oct 06
Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 3.022261 million. Oct 05
Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.715261 million. Sep 29
Recce Pharmaceuticals Completes Dosing in Phase I/II Clinical Trial of Recce® 327 for Urinary Tract Infections Sep 27
Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 8 million. Sep 20 Recce Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 8 million.
Recce Pharmaceuticals Ltd Provides Additional Positive Update on Patients Treated Under "Special Access Scheme" Sep 02
New minor risk - Financial data availability Aug 30
Recce Pharmaceuticals Ltd Announces Safety Committee Approves Next Dose of Recce®? 327 At 3,000Mg in Phase I/Iiuti/Urosepsis Rapid Infusion Clinical Trial Aug 30
Recce Pharmaceuticals Ltd Doses Patients in Phase I/II Clinical Trial of Recce 327 for Diabetic Foot Infections Aug 25
Recce Pharmaceuticals Ltd. Completes Stage 1 Data Analysis of Phase I/II Clinical Trial for the Treatment of Burn Wound Infections Aug 24
Recce Pharmaceuticals Ltd Provides Positive Update on Patients Treated with RECCE®? 327 Under "Special Access Scheme" Aug 11
New major risk - Share price stability Aug 09
Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research Aug 02
Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE(R) 327 as an Intravenous Infusion Formulation Jul 23
Recce Pharmaceuticals Limited Announces First Cohort Dosed in Recce®? 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial Jul 12
CEO, MD & Executive Director recently bought €190k worth of stock Jun 29
Recce Pharmaceuticals to Be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives Jan 12
Recce Pharmaceuticals Limited Announces Australian Patent Office Issued Notification of Intent to Grant Recce's Patent Family 3 Jan 10
Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE(R) 327 in Patients with Diabetic Foot Infections Dec 13
Recce Pharmaceuticals Ltd Receives Ethics Approval to Start Phase I/II Diabetic Foot Ulcer Study Dec 09
Less than half of directors are independent Nov 17 Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update Oct 19
Recce Pharmaceuticals Ltd Provides RECCE 327 SARS-CoV-2 Study Update Oct 18
Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs Sep 27
Recce Pharmaceuticals Ltd, Annual General Meeting, Nov 14, 2022 Sep 21
Recce Pharmaceuticals Appoints Alistair McKeough to Its Board of Directors and Maggie Niewidok as Company Secretary Sep 08
Recce Announces Management Changes Sep 01
Recce Pharmaceuticals Ltd Reports Positive Safety Data from Seventh Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327 Aug 22
Recce Pharmaceuticals Ltd announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE 327 and Initiates Sixth Cohort At 4,000Mg May 20
Less than half of directors are independent Apr 27
Recce Pharmaceuticals Ltd Announces Anti-Viral Patent Granted in Hong Kong Apr 12 Recce Pharmaceuticals Ltd Announces Safety Committee Clears Next Dose in Phase I Study of Recce® 327 Mar 10
Recce Pharmaceuticals Ltd Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327 Jan 20
Recce Pharmaceuticals Ltd Announces Patients to be Dosed in a Phase I Intravenous Clinical Trial of RECCE® 327 Dec 16
Anti-Viral Patent Grants in USA for Recce Pharmaceuticals Ltd's RECCE Anti-Infectives Jul 24
Chinese Patent Office Grants Anti-Viral Patent to Recce Pharmaceuticals Ltd Jul 20
Board Member recently sold €113k worth of stock Jun 23
Recce Pharmaceuticals Ltd. Provides Recce Clinical Pipeline Update Jun 08
Recce Pharmaceuticals Ltd Announces Positive Results of Lead Compound RECCE® 327 May 29
Recce Pharmaceuticals Ltd Announces Further Results for its Synthetic Anti-Infective R327 May 20
Recce Pharmaceuticals Ltd Announces Positive Data on RECCE 327 Against All Six ESKAPE Pathogens May 05
Recce Pharmaceuticals Ltd Announces Lead Compound Recce 327 Added to the Pew Charitable Trusts' Annual List of Non-Traditional Products Mar 15
Recce Pharmaceuticals Ltd Formalizes Fiona Stanley Hospital Phase I/Ii Clinical Trial Agreement Feb 17
Recce Pharmaceuticals Ltd Announces Encouraging Results from Anti-viral Screening Program at The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2 Feb 14
Recce Pharmaceuticals Ltd Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study Dec 25
Recce Pharmaceuticals Ltd Announces Encouraging Preliminary Results from Antiviral Screening Program At the Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2 Nov 12
Recce Pharmaceuticals Ltd Receives Human Research Ethics Committee Approval to Start a Phase I/Ii Clinical Trial of its Broad-Spectrum Antibiotic Recce® 327 on Patients with Infected Burn Wounds Oct 17
New 90-day low: €0.63 Oct 16 Recce Pharmaceuticals Ltd announced that it has received AUD 27.95 million in funding
Recce Pharmaceuticals Ltd announced that it expects to receive AUD 27.95 million in funding Sep 24
New 90-day high - €0.91 Sep 01
Recce Pharmaceuticals Ltd Appoints James Graham as CEO Aug 29 Rendimenti per gli azionisti R9Q DE Pharmaceuticals DE Mercato 7D 7.3% 2.2% 0.7% 1Y -14.8% -16.8% 8.4%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: R9Q ha superato il German Pharmaceuticals che ha restituito -16.8 % nell'ultimo anno.
Rendimento vs Mercato: R9Q ha avuto una performance inferiore al mercato German che ha registrato un rendimento 8.4 % nell'ultimo anno.
Volatilità dei prezzi Is R9Q's price volatile compared to industry and market? R9Q volatility R9Q Average Weekly Movement 12.7% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: Il prezzo delle azioni di R9Q è stato volatile negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 13% ) di R9Q è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni German.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2007 n/a James Graham www.recce.com.au
Recce Pharmaceuticals Ltd, scopre, sviluppa e commercializza antinfettivi sintetici in Australia, Regno Unito e Stati Uniti. Il suo candidato principale è RECCE 327 (R327) per il trattamento delle infezioni del sangue e delle sepsi derivanti dai batteri E. coli e S. aureus, comprese le loro forme superbug. L'azienda sviluppa anche RECCE 529, un antinfettivo sintetico per le infezioni virali, e RECCE 435, un antibiotico polimerico sintetico formulato per uso orale.
Mostra di più Recce Pharmaceuticals Ltd Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Recce Pharmaceuticals con la sua capitalizzazione di mercato? R9Q statistiche fondamentali Capitalizzazione di mercato €68.67m Guadagni(TTM ) -€10.67m Ricavi(TTM ) €3.04m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) R9Q Conto economico (TTM ) Ricavi AU$5.03m Costo del fatturato AU$7.22m Profitto lordo -AU$2.19m Altre spese AU$15.47m Guadagni -AU$17.66m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -0.076 Margine lordo -43.52% Margine di profitto netto -351.24% Rapporto debito/patrimonio netto -101.7%
Come si è comportato R9Q nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/02 11:33 Prezzo dell'azione a fine giornata 2025/01/02 00:00 Guadagni 2024/06/30 Guadagni annuali 2024/06/30
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Recce Pharmaceuticals Ltd è coperta da 2 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Pooya Hemami Edison Investment Research Chris Kallos MST Financial Services Pty Limited
Mostra 0 altri analisti 
